Enanta Pharmaceuticals Toekomstige groei
Future criteriumcontroles 1/6
De winst van Enanta Pharmaceuticals zal naar verwachting dalen met 2.7% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 12.8% per jaar. De winst per aandeel zal naar verwachting groeien met 2.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -64.2% zijn.
Belangrijke informatie
-2.7%
Groei van de winst
2.5%
Groei van de winst per aandeel
Biotechs winstgroei | 27.3% |
Inkomstengroei | 12.8% |
Toekomstig rendement op eigen vermogen | -64.2% |
Dekking van analisten | Good |
Laatst bijgewerkt | 09 Oct 2024 |
Recente toekomstige groei-updates
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Recent updates
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
9/30/2027 | 116 | -112 | -276 | N/A | 4 |
9/30/2026 | 81 | -154 | -230 | N/A | 4 |
9/30/2025 | 74 | -120 | -142 | -100 | 8 |
9/30/2024 | 71 | -112 | -121 | -84 | 8 |
6/30/2024 | 72 | -115 | -100 | -90 | N/A |
3/31/2024 | 73 | -132 | -113 | -107 | N/A |
12/31/2023 | 74 | -138 | -99 | -93 | N/A |
9/30/2023 | 79 | -134 | -112 | -103 | N/A |
6/30/2023 | 81 | -132 | -106 | -97 | N/A |
3/31/2023 | 81 | -125 | -102 | -95 | N/A |
12/31/2022 | 82 | -121 | -112 | -107 | N/A |
9/30/2022 | 86 | -122 | -87 | -85 | N/A |
6/30/2022 | 89 | -120 | -91 | -90 | N/A |
3/31/2022 | 92 | -112 | -91 | -90 | N/A |
12/31/2021 | 93 | -101 | -69 | -68 | N/A |
9/30/2021 | 97 | -79 | -71 | -70 | N/A |
6/30/2021 | 97 | -84 | -65 | -64 | N/A |
3/31/2021 | 94 | -74 | -40 | -39 | N/A |
12/31/2020 | 102 | -58 | -21 | -20 | N/A |
9/30/2020 | 122 | -36 | 6 | 7 | N/A |
6/30/2020 | 150 | 2 | 30 | 31 | N/A |
3/31/2020 | 176 | 24 | 35 | 38 | N/A |
12/31/2019 | 188 | 34 | 48 | 54 | N/A |
9/30/2019 | 205 | 46 | 66 | 71 | N/A |
6/30/2019 | 221 | 65 | 85 | 91 | N/A |
3/31/2019 | 234 | 78 | 88 | 93 | N/A |
12/31/2018 | 238 | 86 | 52 | 55 | N/A |
9/30/2018 | 207 | 72 | 26 | 29 | N/A |
6/30/2018 | 215 | 81 | 56 | 58 | N/A |
3/31/2018 | 166 | 52 | N/A | 49 | N/A |
12/31/2017 | 131 | 34 | N/A | 54 | N/A |
9/30/2017 | 103 | 18 | N/A | 53 | N/A |
6/30/2017 | 40 | -21 | N/A | -7 | N/A |
3/31/2017 | 46 | -13 | N/A | -4 | N/A |
12/31/2016 | 50 | -10 | N/A | 9 | N/A |
9/30/2016 | 88 | 22 | N/A | 36 | N/A |
6/30/2016 | 90 | 29 | N/A | 36 | N/A |
3/31/2016 | 87 | 33 | N/A | 23 | N/A |
12/31/2015 | 132 | 63 | N/A | 112 | N/A |
9/30/2015 | 161 | 79 | N/A | 77 | N/A |
6/30/2015 | 149 | 68 | N/A | 74 | N/A |
3/31/2015 | 180 | 116 | N/A | 123 | N/A |
12/31/2014 | 124 | 82 | N/A | 20 | N/A |
9/30/2014 | 48 | 34 | N/A | 20 | N/A |
6/30/2014 | 46 | 35 | N/A | 23 | N/A |
3/31/2014 | 6 | -19 | N/A | -18 | N/A |
12/31/2013 | 5 | -19 | N/A | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ENTA ( 12.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van ENTA ( 12.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat ENTA binnen 3 jaar verliesgevend zal zijn.